Knowledge Extraction Technologies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Knowledge Extraction Technologies

ADK.V 0.350

-3.4%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

From: Baywall	12/27/2015 3:53:07 PM
	of 4

Diagnos Inc has recently signed a contract with Bayer for diabetic macular edema (DME) and diabetic retinopathy (DR) screening in Colombia. Following this project, they intend to expand the scope of services offered through Bayer into other Latin American countries. Contracts with Novartis are in Mexico, India, Poland and the UAE. In March of this year, Diagnos signed a commercial agreement with a leading ophthalmology pharmaceutical company in the USA. This illustrates that their proprietary computer assisted retinal analysis screening platform (CARA) is being validated by larger companies. The company is well into the process of commercializing with these contracts. I'm optimistic that the company will succeed. Investors are waiting for news from the US where retina screening services to patients are expected through the sponsorship of a major United States based pharmaceutical company. The stock is currently trading at 5.5 cents (Dec. 24, 2015). I use various chart indicators like NVI (Negative Volume Index) and OBV (On Balance Volume) upon which to base my investment decisions. Sometimes I glance at what the Candlestick charts look like. Whenever possible, I try to locate support/resistance levels. The price chart itself and chart indicator action which occur at these levels, can help with investment decisions. This is the opening post to set the background for this Canadian company. I believe 2016 will see inroads being made in the US and elsewhere. I hope this will be reflected in the stock price. CARA is intended to slow or reverse vision impairments in the worldwide diabetic patient population. If caught in the early stages, there's a better chance of a higher treatment success rate.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext